To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer
Clinical trial NCT06389006 · RECRUITING
Trial details
- NCT number
- NCT06389006
- Sponsor
- RemeGen Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-29
- Primary completion
- 2025-06-01
- Enrollment
- 79
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.